Advertisement

Topics

Companies Related to "Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome" [Most Relevant Company Matches] RSS

02:54 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome" found in our extensive corporate database of over 50,000 company records.

Showing "Alendronate Treat Polyostotic Fibrous Dysplasia McCune Albright Syndrome" Companies 1–25 of 1,100+

Extremely Relevant

Miller-McCune

Miller-McCune, a 97,500-circulation national print magazine and its online cousin, Miller-McCune.com, are published by the Miller-McCune Center for Research, Media and Public Policy, a nonprofit public-benefit corporation created by Sara Miller McCune, founder of Sage Publications, a leading international publisher of academic books and journals. In addition to its magazine and Web site, the Santa...


Relevant

Research Down Syndrome

Research Down Syndrome (RDS) is a non-profit foundation which funds research at leading institutions directed towards identifying safe and effective biomedical therapies to treat the intellectual difficulties associated with Down syndrome. RDS' mission is to educate and inspire society to fund and support Down syndrome cognitive research to enhance and expand life opportunities, helping people wit...

Sjogren's Syndrome Foundation

Founded in 1983, the Sjogren's Syndrome Foundation (SSF) provides patients with practical information and coping strategies that minimize the effects of Sjogren's syndrome. In addition, the Foundation is the clearinghouse for medical information and is the recognized national advocate for Sjogren's syndrome. The Foundation's mission is to educate patients and their families about Sjogren's syndrom...


International Hip Dysplasia Institute

Global Down Syndrome Foundation

The Global Down Syndrome Foundation is a public non-profit 501(c)(3) dedicated to significantly improving the lives of people with Down syndrome through research, medical care, education, and advocacy. Formally established in 2009, the Foundation’s primary focus is to support the Linda Crnic Institute for Down Syndrome, the first academic home in the ...

Angelman Syndrome Foundation

Since 1996, the Angelman Syndrome Foundation has funded 59 research grants totaling more than $3.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($3.3 million) beginning in 2005. For more information on the Foundation, please visit www.angelman.org.

International Rett Syndrome Foundation

Rett syndrome (RTT), a brain disorder affecting development in childhood, has been identified almost exclusively in females. RTT results in severe movement and communication problems following apparently normal development for the first six months of life. The characteristic features include loss of speech and purposeful hand use, occurrence of repetitive hand movements, abnormal walking, abnorm...

Discovery Laboratories

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Surfactants are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen.Our humanized surfactant technology is being developed initially for critical care pa...

Down Syndrome Association of Los Angeles

Who: Down Syndrome Association of Los Angeles (DSALA) with National Down Syndrome Society Buddy Walk® Spokesperson John C. McGinley, Dr. Cox on the ABC’s SCRUBS; Grand Marshal, Dr. Jim Sears of THE DOCTORS; Honoring Ken Jenkins, Dr. Kelso of SCRUBS with the Buddy Award, Emcees Mark Wallengren and Kristin Cruz of KOST’s Morning Show, a live dan...

ConSynance Therapeutics Inc.

ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. ConSynance’s pipeline includes innovative treatments for NASH, the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. www.consynance.com

EffRx Pharmaceuticals EffRx Pharmaceuticals SA

EffRx Pharmaceuticals SA is a Swiss-based commercial-stage pharmaceutical company developing and commercializing prescription medications for specialty indications. Our lead commercialized product, Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. We strive to address true un...

Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA...

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy’s lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate ...

Foundation for Angelman Syndrome Therapeutics (FAST)

Angelman Syndrome (AS) was first described by Dr. Harry Angelman in 1965. Common symptoms include developmental delay and intellectual disabilities, happy demeanor, movement and balance disorder, severe sleep disorders, seizures and limited speech. Most children are diagnosed between the ages of 3-5 but early detection and intervention can make a significant difference in the child's development ...

MedAutonomic

MedAutonomic is a privately held medtech company dedicated to developing a bioelectric medicine to treat patients with functional diseases of the metabolic syndrome such as type-2 diabetes, hypertension and gastroesophageal reflux disease (GERD). MedAutonomic’s approach is to offer a nonsurgical alternative treatment of functional diseases with a lowe...

Betagenon AB

Betagenon has secured a strong, proprietary technology platform based upon the extensive research expertise on type 2 diabetes disease mechanisms established by the Founders, leading experts in the field. Betagenon's vision is to become a frontier company that delivers new smart drug platform solutions to the pharmaceutical industry for treatment of the metabolic syndrome and diabetes type 2. Afte...

NPS Pharmaceuticals

NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervous system disorders. History of Successful Drug Discovery NPS has a history of successful drug discovery. With one approved product on the market and several more in development, NPS's discovery capab...

Mati Therapeutics, Inc.

Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is easily inserted into a patient’s punctum. The device has already been approved to treat dry eye syndrome, but Mati is the first to condu...

The International Rett Syndrome Foundation

While there are over 3,800 known cases of Rett Syndrome in the United States which predominantly strikes only girls, the disorder is genetically linked to more widespread neurological disorders such as autism and schizophrenia. Rett symptoms begin to manifest between the first six to eighteen months of life and in most cases will eventually incapacitate the afflicted children so that they can...

Othera Pharmaceuticals

Othera Pharmaceuticals, Inc. is a privately-held U.S. specialty pharmaceutical company focused on the development of innovative new drugs to treat the leading causes of blindness and vision impairment:Dry and wet forms of age-related macular degeneration (AMD) Cataracts Glaucoma Dry eye syndrome Founded in 2002, Othera has progressed rapidly and expects to have as many as eight separate Phase 2 cl...

ADD dental facility

Dr Nick Mohindra first became interested in this field when he was treating patients who were suffering from what is known as TMD syndrome. This is a group of symptoms including sore facial muscles, tense neck and shoulders, or back and head pains, often caused by jaw relationship problems. It occurred to him that the technique he was using to treat these patients could also benefit denture patien...

Alexion Pharmaceuticals Inc.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemo...

Mati Therapeutics Inc.

Mati is developing PPDS, a sustained release ocular drug delivery platform that Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is inserted into a patient’s tear duct (or punctum). The device is already approved to treat dry eye syndrome, but Mati is the first to condu...

Sleep HealthCenters®, Inc.

It is estimated that at least 40 million Americans suffer from a chronic sleep disorder or intermittent sleep-related problem. Sleep deprivation is an unhealthy, dangerous and costly problem.Sleep HealthCenters® is a recognized network of specialized sleep medicine centers, staffed by experts in the field of sleep medicine. Sleep HealthCenters® utilizes the most current technologies available to...

Probably Relevant

Mymetics Corporation

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase...


More From BioPortfolio on "Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks